BIBCL - DAY CHART - 24.12.2022 - BAHAVAN CAPITALBHARAT BIOLOGICAL & IMMUNOLOGICAL CORPORATION As Per Day Chart Analysis ABOVE 46 TARGET 50
Though DII been in selling spree but DII Buying had been highly to be noted
DATE FII DII
21.12.2022 1119.11 cr (Net Selling) 1757.37 cr (Net Buying)
22.12.2022 928.63 cr (Net Buying) 2206.59 cr (Net Buying)
−4.28INR
−170.57 MINR
446.09 MINR
About BHARAT IMMUNOLOGICALS & BIOLOG
Sector
CEO
Dhananjay Kumar Tiwary
Headquarters
Bulandshahr
Website
Founded
1989
ISIN
INE994B01014
FIGI
BBG000DNBJX4
Bharat Immunologicals & Biologicals Corp. Ltd. is a biotechnology company, which engages in the manufacturing and producing pharmaceutical products such as oral polio vaccines; zinc tablet and diarrhea management kit; and ready to use therapeutic food. It operates through the following business segments: Oral Polio Vaccine (OPV), Zinc Tablets, BIB VIT, and BIBSANIT. The company was founded on March 10, 1989 and is headquartered in Bulandshahr, India.
Bharat Biotech - Super Strong Close
Price moving further up to reach the previous ATH and closed strong and no doubt it will move up considerably . . .
I tried to buy this @ 14 -18 rupees and never get a chance, so its only a watch game for me.
Anyone holding this from lower levels can leave a message . . .
Bharat Biotech - Talk of the town - 6 was the best entry.As these guys are getting there vaccines for this pandemic the stocks moves high on every day and there is no chance for the retail traders to get in to the trade.
As you see from the beginning of this stock behavior when these stock reaches 6 levels it bounces back to 50+ levels and then fall back
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BIBCL is 29.68 INR — it has decreased by 2.05% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange BHARAT IMMUNOLOGICALS & BIOLOG stocks are traded under the ticker BIBCL.
BIBCL stock is 4.45% volatile and has beta coefficient of 0.00. Check out the list of the most volatile stocks — is BHARAT IMMUNOLOGICALS & BIOLOG there?
Yes, you can track BHARAT IMMUNOLOGICALS & BIOLOG financials in yearly and quarterly reports right on TradingView.
BIBCL stock has fallen by 5.48% compared to the previous week, the month change is a 6.88% rise, over the last year BHARAT IMMUNOLOGICALS & BIOLOG has showed a 21.14% increase.
BIBCL net income for the last quarter is −49.18 M INR, while the quarter before that showed −45.87 M INR of net income which accounts for −7.22% change. Track more BHARAT IMMUNOLOGICALS & BIOLOG financial stats to get the full picture.
Today BHARAT IMMUNOLOGICALS & BIOLOG has the market capitalization of 1.31 B, it has increased by 3.88% over the last week.
No, BIBCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIBCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BHARAT IMMUNOLOGICALS & BIOLOG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BHARAT IMMUNOLOGICALS & BIOLOG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BHARAT IMMUNOLOGICALS & BIOLOG stock shows the buy signal. See more of BHARAT IMMUNOLOGICALS & BIOLOG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BHARAT IMMUNOLOGICALS & BIOLOG EBITDA is −93.93 M INR, and current EBITDA margin is −35.87%. See more stats in BHARAT IMMUNOLOGICALS & BIOLOG financial statements.